Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
New England Journal of Medicine · 12.09.2024 · 391 (10) · 913-925
DOI: 10.1056/nejmoa2404147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.09.2024. Verfasst von Robert S Rosenson und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York (R.S.R.); Université de …. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Hyperlipidemias, RNAi Therapeutics, Triglycerides. Die Arbeit wurde bisher 228-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York (R.S.R.); Université de Montréal, Montreal (D.G.), and Robarts Research Institute, London, ON…
Förderung
- Arrowhead Pharmaceuticals
Zitieren
APA
Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., Hellawell, J., Watts, G. F., & ARCHES-2 Trial Team (2024). Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391(10), 913-925. https://doi.org/10.1056/nejmoa2404147
Vancouver
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine. 2024;391(10):913-925. doi:10.1056/nejmoa2404147
BibTeX
@article{Rosenson2024,
author = {Rosenson, Robert S and Gaudet, Daniel and Hegele, Robert A and Ballantyne, Christie M and Nicholls, Stephen J and Lucas, Kathryn J and San Martin, Javier and Zhou, Rong and Muhsin, Ma'an and Chang, Ting and Hellawell, Jennifer and Watts, Gerald F and ARCHES-2 Trial Team, ARCHES-2 Trial Team},
title = {Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {10},
pages = {913--925},
doi = {10.1056/nejmoa2404147}
}
EUVIMED